Sato, N., Masuda, N., Morimoto, T., Ueno, T., Kanbayashi, C., Kaneko, K., . . . Toi, M. (2019). Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study. Cancer Med.
Chicago Style citaatSato, Nobuaki, et al. "Neoadjuvant Exemestane or Exemestane Plus Docetaxel and Cyclophosphamide Tailored By Clinicopathological Response to 12 weeks' Exemestane Exposure in Patients With Estrogen Receptor‐positive Breast Cancer: A Multicenter, Open‐label, Phase II Study." Cancer Med 2019.
MLA citatieSato, Nobuaki, et al. "Neoadjuvant Exemestane or Exemestane Plus Docetaxel and Cyclophosphamide Tailored By Clinicopathological Response to 12 weeks' Exemestane Exposure in Patients With Estrogen Receptor‐positive Breast Cancer: A Multicenter, Open‐label, Phase II Study." Cancer Med 2019.